Core Viewpoint - The article highlights the innovative strategies and cultural heritage techniques employed by Guilin Sanjin during the 14th Five-Year Plan period, emphasizing the company's commitment to quality and market expansion in the traditional Chinese medicine sector [2][13]. Group 1: Heritage Techniques Empowering Products - Guilin Sanjin's flagship product, Sanjin Watermelon Frost, has a history of over 200 years, with its modern production techniques improving upon traditional methods to achieve industrial-scale production [4][5]. - The company has successfully integrated modern Chinese medicine theories with traditional craftsmanship, resulting in high-purity products with reduced production cycles and no pollution [5]. - The "Guilin Sanjin Watermelon Frost Production Technique" was included in the Guilin Intangible Cultural Heritage List in 2024, showcasing the company's dedication to preserving and innovating traditional practices [5]. Group 2: Market Strategy and Consumer Focus - The company adopts a "thin profit margin, high sales volume" strategy, ensuring affordable pricing for consumers, with retail prices for Sanjin Watermelon Frost products ranging from a few to several tens of yuan [7]. - Over 90% of pharmacies in China carry Sanjin Watermelon Frost products, reflecting the company's strong market presence and consumer trust built over decades [7]. - The company maintains a comprehensive cost control system across its production processes, allowing it to offer high-quality products at competitive prices [7]. Group 3: Innovation-Driven Development - During the 14th Five-Year Plan, Guilin Sanjin has focused on innovation, establishing a joint innovation platform for traditional Chinese medicine and actively participating in national and regional research projects [9][10]. - The company has made significant advancements in its product lines, with multiple iterations of existing products to enhance efficacy and adapt to market needs [10][11]. - In the biopharmaceutical sector, Guilin Sanjin's subsidiary, Baoshan Biotech, is developing innovative drugs for autoimmune diseases and has received clinical approvals for several products [10][11]. Group 4: Supply Chain and Distribution - Guilin Sanjin employs a competitive bidding process for sourcing raw materials, ensuring quality and cost-effectiveness in its supply chain [12]. - The company has established a robust distribution network with nearly 100 main distributors and over a thousand sub-distributors, facilitating widespread market access [12]. - Currently, 18 of the company's products are registered and sold in 17 countries and regions, enhancing its international presence [13].

Core Viewpoint - Guilin Sanjin is leveraging traditional craftsmanship and innovative strategies to enhance product quality and drive growth during the 14th Five-Year Plan period [3][10]. Group 1: Product Innovation and Heritage - The company's flagship product, Sanjin Watermelon Frost, has a history of over 200 years and has been modernized through innovative production techniques that ensure high purity and effectiveness while reducing production time and environmental impact [3][4]. - Guilin Sanjin's commitment to traditional techniques has led to the successful inclusion of "Guilin Sanjin Watermelon Frost Production Technique" in the Guilin Intangible Cultural Heritage list in 2024, affirming the company's role in preserving and revitalizing traditional Chinese medicine [3][10]. Group 2: Market Strategy and Consumer Focus - The company adopts a "thin profit margin, high sales volume" strategy, ensuring affordable pricing for its products, which are widely available in over 90% of pharmacies across China [6][10]. - Sanjin Watermelon Frost and Sanjin Tablets have been market leaders for over 30 years, achieving a stable market share due to their consistent efficacy and consumer trust [6][10]. Group 3: Research and Development - During the 14th Five-Year Plan, Guilin Sanjin has received multiple awards for its research projects, highlighting its strong capabilities in scientific innovation [5][10]. - The company is actively involved in the development of innovative drugs and has made significant improvements to existing products, with Sanjin Watermelon Frost undergoing eight rounds of innovation [8][9]. Group 4: Supply Chain and Distribution - Guilin Sanjin maintains a robust supply chain with long-term relationships with suppliers, ensuring a steady supply of key raw materials for its products [10]. - The company has established a mature distribution network with nearly 100 main distributors and over 2,000 chain pharmacies, facilitating its market reach [10]. Group 5: International Expansion - Guilin Sanjin has successfully registered and launched 18 products in 17 countries and regions, expanding its presence in markets along the Belt and Road Initiative [10].

Core Viewpoint - Guilin Sanjin (002275) has confirmed that its products are sold in various overseas markets, including Eastern Europe, North America, Oceania, and Southeast Asia, but currently does not have sales in Japan and South Korea, nor any related foreign enterprise consultation or agency cooperation [1] Group 1 - The company has a presence in overseas markets such as Serbia, the United States, Canada, Australia, and most Southeast Asian countries [1] - There is currently no sales activity in Japan and South Korea [1] - The company has not engaged in any foreign enterprise consultation or agency cooperation for these regions [1]

证券日报网讯 桂林三金（002275）9月26日在互动平台回答投资者提问时表示，公司目前没有授权国外 企业生产相关产品，公司产品桂林西瓜霜（喷剂）具有清热解毒、消肿止痛之功效，用于急、慢性咽 炎，扁桃体炎，口腔炎，口腔溃疡等。是否可替代西药建议根据个人病情咨询医生或药师。 ...

格隆汇9月26日丨桂林三金(002275.SZ)在互动平台表示，公司目前没有授权国外企业生产相关产品，公 司产品桂林西瓜霜（喷剂）具有清热解毒、消肿止痛之功效，用于急、慢性咽炎，扁桃体炎，口腔炎， 口腔溃疡等。 ...

桂林三金（002275.SZ）9月26日在投资者互动平台表示，公司产品在海外很多市场都有销售，如东欧的 塞尔维亚、美洲的美国和加拿大、大洋洲的澳大利亚、东南亚地区大部分国家等。但是目前没有在日韩 地区销售，也没有相关外企咨询合作代理。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问桂林三金西瓜霜含片是否在日韩有销售，是否有 相关国外企业咨询合作代理？ ...

Group 1 - The company is currently in the market development stage for its toothpaste business, specifically the Xigua Frost toothpaste under its subsidiary, Daily Chemical Health Products [2] - The expected sales for the toothpaste in 2024 are nearly 40 million yuan, which represents a small proportion of the company's overall revenue, indicating limited contribution to performance improvement [2] - The company plans to continue optimizing its product structure, accelerate the layout of distribution channels, actively expand e-commerce channels, and enhance the terminal brand image to achieve stable and continuous sales growth [2]

Core Viewpoint - Guilin Sanjin (002275.SZ) is in the market development phase for its Watermelon Frost toothpaste, which is a product of its subsidiary in the personal care sector. The sales contribution of this toothpaste is currently limited, accounting for nearly 40 million yuan of the company's total revenue, which is a small proportion. The company aims to optimize its product structure and enhance its distribution channels, particularly in e-commerce, to achieve stable sales growth in the future [1]. Group 1 - The Watermelon Frost toothpaste is still in the market development stage [1] - The sales revenue from the toothpaste is approximately 40 million yuan, representing a small portion of overall revenue [1] - The company plans to optimize product structure and accelerate channel layout to boost sales [1] Group 2 - The company is actively expanding its e-commerce channels [1] - There is a focus on improving the brand image at the terminal level [1] - The goal is to achieve continuous and stable growth in sales [1]

Core Viewpoint - Guilin Sanjin (002275.SZ) is in the market expansion phase for its subsidiary's product, Xigua Frost toothpaste, which currently contributes limited revenue to the overall performance of the company [1] Group 1: Product and Sales Performance - The sales revenue of Xigua Frost toothpaste is nearly 40 million yuan, representing a small proportion of the company's total revenue [1] - The contribution of toothpaste sales to the company's performance is limited at this stage [1] Group 2: Future Strategies - The company plans to continue optimizing its product structure and accelerate the layout of distribution channels [1] - There is an active effort to expand e-commerce channels and enhance the terminal brand image [1] - The goal is to achieve sustained and stable growth in sales moving forward [1]

Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is located in the Lingui District of Guilin City, Guangxi Zhuang Autonomous Region, established on February 23, 1994, and listed on July 10, 2009 [2] - The company specializes in the research, production, and sales of traditional Chinese medicine products, including throat and oral medications, anti-urinary tract infection drugs, and cardiovascular drugs, along with other natural medicines and biological preparations [2] - The main business revenue composition is as follows: Industrial 97.26%, Commodity circulation 2.37%, Other 0.38% [2] Stock Performance - As of September 23, the stock price of Guilin Sanjin fell by 2.11%, trading at 14.35 CNY per share, with a total market capitalization of 8.432 billion CNY [1] - Year-to-date, the stock price has decreased by 2.65%, with a 4.01% drop over the last five trading days and a 7.66% decline over the last 20 days [2] - The stock has appeared on the "Dragon and Tiger List" once this year, with the last appearance on January 7, where it recorded a net buy of -177.741 million CNY [2] Financial Performance - For the first half of 2025, Guilin Sanjin reported a revenue of 999.8 million CNY, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million CNY, down 4.70% year-on-year [3] - The company has distributed a total of 4.592 billion CNY in dividends since its A-share listing, with 1.175 billion CNY distributed over the last three years [4] Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, with an average of 25,628 circulating shares per shareholder, an increase of 0.78% [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [4] Market Position - Guilin Sanjin is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [2] - The company is associated with several concept sectors, including anti-influenza, traditional Chinese medicine, small-cap stocks, innovative drugs, and margin financing [2]